SeaStar Medical will report Q4 2024 financial results on March 27, 2025, and host a conference call to discuss.
Quiver AI Summary
SeaStar Medical Holding Corporation announced that it will release its fourth quarter and year-end 2024 financial results on March 27, 2025, after market close, followed by a webcast and conference call at 4:30 p.m. ET to discuss its performance and business updates. The company, which focuses on innovative treatments for critically ill patients with organ failure, recently received FDA approval for its product QUELIMMUNE (SCD-PED), designed to treat life-threatening acute kidney injury in critically ill pediatric patients. SeaStar is also advancing its Selective Cytopheretic Device therapy, which has received Breakthrough Device Designation from the FDA for multiple indications, and is conducting a pivotal trial for adult patients with acute kidney injury. Further information can be found on their website and social media channels.
Potential Positives
- SeaStar Medical's QUELIMMUNE product received FDA approval in 2024, making it the only FDA-approved treatment for life-threatening acute kidney injury in critically ill pediatric patients.
- The company has been awarded Breakthrough Device Designation for four indications, potentially accelerating the approval process for new therapies and enhancing reimbursement prospects.
- SeaStar is conducting a pivotal trial for its SCD therapy in adult patients with AKI, addressing a significant unmet medical need affecting over 200,000 adults in the U.S. annually.
Potential Negatives
- Company is announcing financial results after the market close, which may lead to negative speculation about performance if results are disappointing.
- SeaStar Medical is focused on an ultra-rare condition, which could limit market potential and revenue compared to broader therapeutic areas.
- The mention of conducting a pivotal trial indicates ongoing development challenges and the need for further validation of its therapies, which could delay financial performance.
FAQ
When will SeaStar Medical release its 2024 financial results?
SeaStar Medical will release its 2024 financial results on March 27, 2025, after market close.
How can I access SeaStar Medical's financial results conference call?
You can access the conference call by dialing 1 (800) 715-9871 within the U.S. or 1 (646) 307-1963 from outside the U.S.
What is QUELIMMUNE and its significance?
QUELIMMUNE is SeaStar's FDA-approved product for treating life-threatening acute kidney injury in critically ill pediatric patients.
What therapeutic indications does SeaStar's SCD therapy cover?
SeaStar's Selective Cytopheretic Device therapy has been granted Breakthrough Device Designation for four therapeutic indications by the FDA.
Where can I find more information about SeaStar Medical?
For more information, visit www.seastarmedical.com or check their LinkedIn and X profiles.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- JOHN NEUMAN purchased 10,000 shares for an estimated $20,405
- KEVIN CHUNG (Chief Medical Officer) has made 2 purchases buying 5,250 shares for an estimated $12,715 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ICU Analyst Ratings
Wall Street analysts have issued reports on $ICU in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 12/11/2024
To track analyst ratings and price targets for $ICU, check out Quiver Quantitative's $ICU forecast page.
Full Release
DENVER, March 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT |
| Webcast: | The live webcast and replay can be found here . |
| Conference ID: | 2078693 |
| Dial-in numbers: | 1 (800) 715-9871 within the U.S. |
| 1 (646) 307-1963 from outside the U.S. | |
A replay of the call will be available after 7:30 pm ET and can be accessed as follows:
- The webcast replay is available here .
- The call replay number is 1 (609) 800-9909 and will be available through April 3, 2025.
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
SeaStar Investor Relations:
[email protected]
